For inclusion in 2023’s list, an asset had to be wholly owned, outside of clinical trial collaborations or small, regional tie-ups, and its developer unlikely to want to launch alone. The table was based on the net present value of the assets, as computed by Evaluate. In Vivo spotlighted 10 assets that could draw attention from dealmakers.
Reviewing the 2023 table, three assets have lost value, according to NPV analysis from Evaluate. These are: Ventyx Biosciences, Inc.’s VTX958, uniQure N.V.’s AMT-130 and ALX Oncology, Inc.’s evorpacept. Of these drugs, VTX958 has been the biggest casualty; Ventyx has suspended development in all indications.